144 related articles for article (PubMed ID: 26491856)
41. Eltrombopag in patients with chronic liver disease.
Giannini EG; Afdhal NH
Expert Opin Pharmacother; 2013 Apr; 14(5):669-78. PubMed ID: 23452139
[TBL] [Abstract][Full Text] [Related]
42. Platelet activation and function during eltrombopag treatment in immune thrombocytopenia.
Haselboeck J; Pabinger I; Ay C; Koder S; Panzer S
Ann Hematol; 2012 Jan; 91(1):109-13. PubMed ID: 21553010
[TBL] [Abstract][Full Text] [Related]
43. Eltrombopag for the treatment of immune thrombocytopenia.
Cheng G
Expert Rev Hematol; 2011 Jun; 4(3):261-9. PubMed ID: 21671710
[TBL] [Abstract][Full Text] [Related]
44. Supportive Care and Newer Therapies in Aplastic Anaemia.
Malhotra P; John JM
J Assoc Physicians India; 2015 Mar; 63(3 Suppl):26-9. PubMed ID: 26529864
[No Abstract] [Full Text] [Related]
45. Do we have to worry for thrombocytopenia during treatment of hepatitis C.
Ince AT
Turk J Gastroenterol; 2014 Jun; 25(3):344-5. PubMed ID: 25141332
[No Abstract] [Full Text] [Related]
46. Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
Jolliffe E; Romeril K
Intern Med J; 2014 Jul; 44(7):697-9. PubMed ID: 25041772
[TBL] [Abstract][Full Text] [Related]
47. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
48. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
Geng W; Kearney S; Nelson S
Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285
[TBL] [Abstract][Full Text] [Related]
49. Is treatment of moderate thrombocytopenia indicated for patients with HCV infection and cirrhosis?
Desborough MJ; Jairath V
Gastroenterology; 2014 Jul; 147(1):254. PubMed ID: 24877869
[No Abstract] [Full Text] [Related]
50. Reply: To PMID 24126097.
Afdhal NH; Theodore D
Gastroenterology; 2014 Jul; 147(1):255-6. PubMed ID: 24877870
[No Abstract] [Full Text] [Related]
51. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
Cela I; Miller IJ; Katz RS; Rizman A; Shammo JM
Clin Adv Hematol Oncol; 2010 Nov; 8(11):806-9. PubMed ID: 21326158
[No Abstract] [Full Text] [Related]
52. Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia.
Zaninetti C; Barozzi S; Bozzi V; Gresele P; Balduini CL; Pecci A
Am J Hematol; 2019 Aug; 94(8):E199-E201. PubMed ID: 31034630
[No Abstract] [Full Text] [Related]
53. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
Serebruany VL; Eisert C; Sabaeva E; Makarov L
Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
[TBL] [Abstract][Full Text] [Related]
54. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
Imbach P; Crowther M
N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
[No Abstract] [Full Text] [Related]
55. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
56. Successful eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease.
El Rassy E; Kourie HR; Nehme W; Georges S; Haddad E; Nasnas R; Nasr F
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):e23-4. PubMed ID: 25497274
[No Abstract] [Full Text] [Related]
57. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.
Saleh MI; Obeidat AR; Anter HA; Khanfar AA
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):1030-5. PubMed ID: 26173631
[TBL] [Abstract][Full Text] [Related]
58. Update on eltrombopag for ITP.
Bussel JB
Oncology (Williston Park); 2009 Nov; 23(13):1177-8. PubMed ID: 20043469
[No Abstract] [Full Text] [Related]
59. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
[No Abstract] [Full Text] [Related]
60. Treatment of Severe Refractory Thrombocytopenia in Brucellosis with Eltrombopag: A Case Report.
Zhang XW; Ren P; Huang TL
Pediatr Infect Dis J; 2022 Aug; 41(8):e332-e335. PubMed ID: 35421043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
